Metvix Daylight PDT in Actinic Keratosis
Completed
- Conditions
- Actinic Keratosis
- Registration Number
- NCT02674048
- Lead Sponsor
- Galderma R&D
- Brief Summary
Prospective non-interventional study conducted in Australia, Brazil, Mexico and Europe to evaluate clinical practice with Metvix Daylight PDT in the treatment of mild to moderate actinic keratosis of the face/scalp and to assess physician and patient satisfaction.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 406
Inclusion Criteria
- Patients to whom Metvix® Daylight-PDT has already been prescribed by their physician, according to the local label;
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of physician satisfaction assessed on a 4-point scale from very satisfied to not satisfied with the question "Overall are you satisfied with Metvix DL-PDT?" 3 months Percentage of patient satisfisfaction assessed on a 4-point scale from very satisfied to not satisfied with the question "Overall, how satisfied are you with this treatment?". 3 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Metvix Daylight PDT in treating actinic keratosis?
How does Metvix Daylight PDT compare to 5-aminolevulinic acid-based PDT for actinic keratosis in terms of efficacy and patient satisfaction?
Are there specific biomarkers that correlate with improved outcomes in patients treated with Metvix Daylight PDT for facial and scalp actinic keratosis?
What are the most common adverse events associated with Metvix Daylight PDT in actinic keratosis and how are they managed in clinical practice?
What is the role of Galderma R&D in advancing daylight photodynamic therapy for non-melanoma skin cancers like actinic keratosis compared to other pharmaceutical companies?
Trial Locations
- Locations (7)
See Jo-Ann
🇦🇺Sydney, New South Wales, Australia
France
🇫🇷Pontoise, France
Italy
🇮🇹L'Aquila, Italy
Alkmaar
🇳🇱Alkmaar, Netherlands
Madrid
🇪🇸Madrid, Spain
Bern
🇨🇭Bern, Switzerland
Manchester
🇬🇧Manchester, United Kingdom
See Jo-Ann🇦🇺Sydney, New South Wales, Australia